[go: up one dir, main page]

CO2022012006A2 - Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético - Google Patents

Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético

Info

Publication number
CO2022012006A2
CO2022012006A2 CONC2022/0012006A CO2022012006A CO2022012006A2 CO 2022012006 A2 CO2022012006 A2 CO 2022012006A2 CO 2022012006 A CO2022012006 A CO 2022012006A CO 2022012006 A2 CO2022012006 A2 CO 2022012006A2
Authority
CO
Colombia
Prior art keywords
quinazolin
piperazin
methoxyphenyl
trifluoromethyl
fluoro
Prior art date
Application number
CONC2022/0012006A
Other languages
English (en)
Inventor
Helmut Buschmann
Thomas Goldner
Bertran Jordi Carles Ceron
Original Assignee
Aic246 Ag & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aic246 Ag & Co Kg filed Critical Aic246 Ag & Co Kg
Publication of CO2022012006A2 publication Critical patent/CO2022012006A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a la sal de potasio del ácido 2-[(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4H-quinazolin-4-il] acético y solvatos de la misma. La invención se refiere además a métodos de preparación de dicha sal de potasio del ácido 2-[(4S)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4H-quinazolin-4-il] acético o solvatos de la misma, así como composiciones farmacéuticas que comprenden dicha sal.
CONC2022/0012006A 2020-02-27 2022-08-23 Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético CO2022012006A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20159742 2020-02-27
PCT/EP2021/055078 WO2021170882A1 (en) 2020-02-27 2021-03-01 Potassium salt of 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetic acid

Publications (1)

Publication Number Publication Date
CO2022012006A2 true CO2022012006A2 (es) 2022-11-18

Family

ID=69742731

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0012006A CO2022012006A2 (es) 2020-02-27 2022-08-23 Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético

Country Status (21)

Country Link
US (1) US20230150950A1 (es)
EP (1) EP4110471A1 (es)
JP (1) JP7512405B2 (es)
KR (1) KR20220148860A (es)
CN (1) CN115427112B (es)
AR (1) AR121437A1 (es)
AU (1) AU2021227281B2 (es)
BR (1) BR112022016890A2 (es)
CA (1) CA3169075A1 (es)
CL (1) CL2022002294A1 (es)
CO (1) CO2022012006A2 (es)
CU (1) CU20220046A7 (es)
EC (1) ECSP22066666A (es)
IL (1) IL295644A (es)
MX (1) MX2022010442A (es)
MY (1) MY210500A (es)
NZ (1) NZ792572A (es)
PE (1) PE20230512A1 (es)
TW (1) TWI819279B (es)
UY (1) UY39097A (es)
WO (1) WO2021170882A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR128035A1 (es) * 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
WO2025133248A1 (en) 2023-12-21 2025-06-26 Aic246 Ag & Co. Kg Diastereomeric aminoalcohol and aminoether salts of 2-[(4r,s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl]acetic acid and their use for enantiomeric separation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE102005027517A1 (de) 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats

Also Published As

Publication number Publication date
AU2021227281B2 (en) 2024-07-18
KR20220148860A (ko) 2022-11-07
AU2021227281A1 (en) 2022-10-13
UY39097A (es) 2021-09-30
TWI819279B (zh) 2023-10-21
BR112022016890A2 (pt) 2022-12-06
MY210500A (en) 2025-09-26
WO2021170882A1 (en) 2021-09-02
PE20230512A1 (es) 2023-03-24
CU20220046A7 (es) 2023-04-10
JP7512405B2 (ja) 2024-07-08
CN115427112B (zh) 2024-10-11
CA3169075A1 (en) 2021-09-02
US20230150950A1 (en) 2023-05-18
NZ792572A (en) 2025-07-25
IL295644A (en) 2022-10-01
AR121437A1 (es) 2022-06-08
CL2022002294A1 (es) 2023-02-03
ECSP22066666A (es) 2022-12-30
EP4110471A1 (en) 2023-01-04
MX2022010442A (es) 2022-10-18
JP2023524349A (ja) 2023-06-12
TW202140455A (zh) 2021-11-01
CN115427112A (zh) 2022-12-02

Similar Documents

Publication Publication Date Title
CY1117796T1 (el) Μετα νατριου και ασβεστιου αλατα παραγωγου διυδροκινζολινης και η χρηση αυτων ως αντι-ιικα μεσα
CO2022012006A2 (es) Sal de potasio del ácido 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acético
CY1121071T1 (el) Παραγωγα ναφθυριδινης ως ανταγωνιστες ιντεγκρινης αλφα v βητα 6 για τη θεραπεια π.χ. ινωτικων νοσων
CO6280440A2 (es) Derivados de aminobenzamida como agentes utiles para el control de parasito de animales
MX2015011478A (es) Compuestos de amida para el tratamiento de vih.
PE20160863A1 (es) Proceso para la sintesis de un inhibidor de indolamina 2,3-dioxigenasa
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
EA201992128A1 (ru) Конденсированные имидазопиперидиновые ингибиторы jak
NZ628444A (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
CL2012000821A1 (es) Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; uso de la composicion inmunogenica que sirve para preparar un medicamento util para tratar afecciones de infeccion por prv en un animal.
CY1118284T1 (el) Βεσυλικα και τοσυλικα αλατα ενος παραγωγου διυδροκιναζολινης και χρηση αυτων ως αντιικων παραγοντων
MX2024005304A (es) Derivado del acido fenilpropionico sustituido y uso del mismo.
BRPI0507574A (pt) piridazinonas como antagonistas de alfa 4 integrinas
PE20211757A1 (es) Formas cristalinas y formas de sal de un inhibidor de cinasa
EA201890386A1 (ru) Ингибитор мутированной изоцитратдегидрогеназы idh1 r132h
BR112017003242A2 (pt) composto, métodos para tratar infecção por vírus e para fabricação de um medicamento, composição farmacêutica, e, uso de um composto.
CL2024000755A1 (es) Sal de calcio de ácido 2-[4-[(5,6-difenilpirazin-2-il)-propan-2-ilamino]butoxi]acético
EA201491288A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ, СОДЕРЖАЩИЙ БРЕКСПИПРАЗОЛ И ЗАМЕЩЕННЫЙ β-ЦИКЛОДЕКСТРИН
JOP20200079A1 (ar) مثبطات مستقبل عامل نمو البشرة
MX385295B (es) Expresión recombinante de la proteína orf2 de pcv2b en células de insecto.
EA201992744A1 (ru) Фармацевтические композиции n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и его солей
PE20190452A1 (es) Derivado de triazolopirazinona util como un inhibidor de pde1 humana
EA201990652A1 (ru) Фармацевтическая композиция, содержащая два различных активных ингредиента, и способ ее получения
BR112022016868A2 (pt) Composições farmacêuticas que compreendem 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-l-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il]acetato e íons de sódio
ECSP22066670A (es) 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso